San Antonio, Texas USA (UroToday.com) Peter Pinto, National Cancer Institute, discussed imaging and focal therapy in particular utilization of multiparametric magnetic resonance imaging (mpMRI) in prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The traditional imaging was transrectal ultrasound. mpMRI correlation with whole-mount prostatectomy specimens highlights the accuracy of this imaging modality. MRI-fusion platforms have exploited this technology to enhance detection of clinically significant disease. Furthermore, focal ablation can treat these targeted areas in select patients deemed suitable candidates. However, mpMRI is not perfect and may miss clinically significant disease and further research and clinical trial data are needed prior to focal ablation becoming standard of care.
Presented by: Peter Pinto, National Cancer Institute
Written By: Stephen B. Williams, MD and Ashish M. Kamat
17th Annual Meeting of the Society of Urologic Oncology - November 30 -December 2, 2016 – San Antonio, Texas USA